Efficacy and Safety of Coadministered Amlodipine and Atorvastatin in Patients With Hypertension and Dyslipidemia: Results of the AVALON Trial

The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia. Phase one was an 8‐week, double‐blind, double‐dummy, placebo‐controlled period whereby patients received amlodipine 5 m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of clinical hypertension (Greenwich, Conn.) Conn.), 2006-08, Vol.8 (8), p.571-583
Hauptverfasser: Messerli, Franz H., Bakris, George L., Ferrera, R. David, Houston, Mark C., Petrella, Robert J., Flack, John M., Sun, William, Lee, EunMee, Neutel, Joel M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia. Phase one was an 8‐week, double‐blind, double‐dummy, placebo‐controlled period whereby patients received amlodipine 5 mg, atorvastatin 10 mg, amlodipine 5 mg and atorvastatin 10 mg, or placebo. Thereafter, all patients received single‐blind amlodipine 5 mg and atorvastatin 10 mg for 8‐weeks, followed by 12 weeks of open‐label treatment where doses could be titrated to improve low‐density lipoprotein cholesterol and blood pressure control. A total of 847 patients entered the double‐blind phase. At Week 8, 45% of the patients receiving amlodipine 5 mg and atorvastatin 10 mg reached both their blood pressure and low‐density lipoprotein cholesterol goals, compared with 8.3% with amlodipine (p
ISSN:1524-6175
1751-7176
DOI:10.1111/j.1524-6175.2006.05636.x